PCSK9: A new participant in lipophagy in regulating atherosclerosis?

被引：10
作者：
Xiao, Jun [1 ]
Deng, Yi-Min [1 ]
Liu, Xiang-Rui [1 ]
Cao, Jian-Ping [2 ]
Zhou, Min [1 ]
Tang, Ya-Ling [1 ]
Xiong, Wen-Hao [1 ]
Jiang, Zhi-Sheng [1 ]
Tang, Zhi-Han [1 ]
Liu, Lu-Shan [1 ]
机构：
[1] Univ South China, Hunan Int Sci & Technol Cooperat Base Arterioscle, Key Lab Arteriosclerol Hunan Prov, Inst Cardiovasc Dis, Hengyang 421001, Hunan, Peoples R China
[2] Hunan Environm Biol Vocat & Tech Coll, Hengyang 421001, Hunan, Peoples R China
来源：
CLINICA CHIMICA ACTA | 2019年 / 495卷
基金：
中国国家自然科学基金;
关键词：
Proprotein convertase subtilisin kexin 9; Lipophagy; Lipid metabolism; Low density lipoprotein receptor; Atherosclerosis; SUBTILISIN/KEXIN TYPE 9; LIPID DROPLETS; ENDOPLASMIC-RETICULUM; INCREASED EXPRESSION; APOLIPOPROTEIN-B; RAB7; EFFECTOR; LIVER-DISEASE; AUTOPHAGY; PROTEIN; DEGRADATION;
D O I：
10.1016/j.cca.2019.05.005
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
Proprotein convertase subtilisin kexin 9 (PCSK9) regulates lipid metabolism by degrading low-density lipoprotein receptor on the surface of hepatocytes. PCSK9-mediated lipid degradation is associated with lipophagy. Lipophagy is a process by which autophagosomes selectively sequester lipid-droplet-stored lipids and are delivered to lysosomes for degradation. Lipophagy was first discovered in hepatocytes, and its occurrence provides important fundamental insights into how lipid metabolism regulates cellular physiology and pathophysiology. Furthermore, PCSK9 may regulate lipid levels by affecting lipophagy. This review will discuss recent advances by which PCSK9 mediates lipid degradation via the lipophagy pathway and present lipophagy as a potential therapeutic target for atherosclerosis.
引用
收藏
页码：358 / 364
页数：7
相关论文
共 50 条
[41]   Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis [J].
Lu, Xinjie .
CURRENT DRUG TARGETS, 2019, 20 (10) :1029-1040
[42]   PCSK9 in metabolism and diseases [J].
Ajoolabady, Amir ;
Pratico, Domenico ;
Mazidi, Mohsen ;
Davies, Ian G. ;
Lip, Gregory Y. H. ;
Seidah, Nabil ;
Libby, Peter ;
Kroemer, Guido ;
Ren, Jun .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2025, 163
[43]   PCSK9 Association With Lipoprotein(a) [J].
Tavori, Hagai ;
Christian, Devon ;
Minnier, Jessica ;
Plubell, Deanna ;
Shapiro, Michael D. ;
Yeang, Calvin ;
Giunzioni, Ilaria ;
Croyal, Mikael ;
Duell, P. Barton ;
Lambert, Gilles ;
Tsimikas, Sotirios ;
Fazio, Sergio .
CIRCULATION RESEARCH, 2016, 119 (01) :29-+
[44]   Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPARγ, LXRα and ABCA1 [J].
Jia, Qingling ;
Cao, Hui ;
Shen, Dingzhu ;
Li, Shanshan ;
Yan, Li ;
Chen, Chuan ;
Xing, Sanli ;
Dou, Fangfang .
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2019, 44 (03) :893-902
[45]   A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis [J].
Wang, Wei-zhi ;
Liu, Chao ;
Luo, Jin-que ;
Lei, Li-juan ;
Chen, Ming-hua ;
Zhang, Yu-yan ;
Sheng, Ren ;
Li, Yi-ning ;
Wang, Li ;
Jiang, Xin-hai ;
Xiao, Tong-mei ;
Zhang, Yu-hao ;
Li, Shun-wang ;
Wu, Ye-xiang ;
Xu, Yang ;
Xu, Yan-ni ;
Si, Shu-yi .
ACTA PHARMACOLOGICA SINICA, 2024, 45 (10) :2119-2133
[46]   Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes [J].
Tang, Ying ;
Li, Sheng-Lan ;
Hu, Jia-Hui ;
Sun, Kai-Jun ;
Liu, Lei-Ling ;
Xu, Dan-Yan .
CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
[47]   Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis [J].
Wu, Yue ;
Xu, Ming-Jiang ;
Cao, Zhiyou ;
Yang, Chun ;
Wang, Jinjie ;
Wang, Bijue ;
Liu, Jian ;
Wang, Yuhui ;
Xian, Xunde ;
Zhang, Fang ;
Liu, George ;
Chen, Xiaoli .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (23)
[48]   PCSK9 as a New Player in Cancer: New Opportunity or Red Herring? [J].
Bonaventura, Aldo ;
Vecchie, Alessandra ;
Ruscica, Massimiliano ;
Grossi, Francesco ;
Dentali, Francesco .
CURRENT MEDICINAL CHEMISTRY, 2022, 29 (06) :960-969
[49]   Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study [J].
Ko, Dennis T. ;
Khan, Anam M. ;
Kotrri, Gynter ;
Austin, Peter C. ;
Wijeysundera, Harindra C. ;
Koh, Maria ;
Chu, Anna ;
Jackevicius, Cynthia A. ;
Lawler, Patrick R. ;
Tu, Jack V. .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (21)
[50]   PCSK9 in HIV infection: New opportunity or red herring? [J].
Ruscica, Massimiliano ;
Watts, Gerald F. ;
Sirtori, Cesare R. .
ATHEROSCLEROSIS, 2019, 284 :216-217
12345